MA45185A - Composé de sulfonamide ou son sel - Google Patents

Composé de sulfonamide ou son sel

Info

Publication number
MA45185A
MA45185A MA045185A MA45185A MA45185A MA 45185 A MA45185 A MA 45185A MA 045185 A MA045185 A MA 045185A MA 45185 A MA45185 A MA 45185A MA 45185 A MA45185 A MA 45185A
Authority
MA
Morocco
Prior art keywords
salt
sulfonamide compound
sulfonamide
compound
Prior art date
Application number
MA045185A
Other languages
English (en)
Inventor
Shoki Hara
Seiji Miyahara
Yoshio Ogino
Hiroyuki Ueno
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA45185A publication Critical patent/MA45185A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA045185A 2016-05-31 2017-05-30 Composé de sulfonamide ou son sel MA45185A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2016109609 2016-05-31

Publications (1)

Publication Number Publication Date
MA45185A true MA45185A (fr) 2019-04-10

Family

ID=60478546

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045185A MA45185A (fr) 2016-05-31 2017-05-30 Composé de sulfonamide ou son sel

Country Status (21)

Country Link
US (1) US11634395B2 (fr)
EP (1) EP3466934B1 (fr)
JP (1) JP6532607B2 (fr)
KR (2) KR102543559B1 (fr)
CN (1) CN109563057B (fr)
AU (1) AU2017275209C1 (fr)
CA (1) CA3025887C (fr)
DK (1) DK3466934T3 (fr)
ES (1) ES2982299T3 (fr)
FI (1) FI3466934T3 (fr)
HU (1) HUE067028T2 (fr)
MA (1) MA45185A (fr)
MX (1) MX385269B (fr)
MY (1) MY194676A (fr)
PH (1) PH12018502513A1 (fr)
PL (1) PL3466934T3 (fr)
PT (1) PT3466934T (fr)
RU (1) RU2732572C2 (fr)
SG (1) SG11201810704WA (fr)
TW (1) TWI746562B (fr)
WO (1) WO2017209155A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017275209C1 (en) 2016-05-31 2020-01-23 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
US20200405697A1 (en) * 2017-11-29 2020-12-31 Taiho Pharmaceutical Co., Ltd. Antitumor Agent
AU2018377036B2 (en) * 2017-11-29 2022-04-14 Taiho Pharmaceutical Co., Ltd. Sulfonamide compounds and use thereof
WO2020109039A1 (fr) 2018-11-28 2020-06-04 Basf Se Composés pesticides
CN109608352A (zh) * 2018-12-28 2019-04-12 凯瑞斯德生化(苏州)有限公司 一种2,6-二甲基-l-酪氨酸的制备方法
CN110066308B (zh) * 2019-04-26 2022-05-27 上海药明康德新药开发有限公司 用于DNA编码化合物库构建中的On-DNA磺酰胺类化合物的合成方法
KR102748684B1 (ko) * 2019-05-29 2025-01-02 다이호야쿠힌고교 가부시키가이샤 술폰아미드 화합물과 면역 조절제를 사용하는 암 병용 요법
CN115443267B (zh) 2020-04-28 2025-09-05 巴斯夫欧洲公司 杀害虫化合物
WO2022187200A1 (fr) * 2021-03-02 2022-09-09 Boundless Bio, Inc. Inhibiteurs de ribonucléotide réductase (rnr) et leurs utilisations
TW202328121A (zh) * 2021-09-17 2023-07-16 美商無界生物公司 環狀磺醯胺核糖核苷酸還原酶(rnr)抑制劑及其用途
WO2023043938A1 (fr) * 2021-09-17 2023-03-23 Boundless Bio, Inc. Inhibiteurs de ribonucléotide réductase (rnr) de sulfamide et leurs utilisations
JP2025531147A (ja) * 2022-09-13 2025-09-19 バウンドレス バイオ，インク． 環状スルホンアミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用
CN117024616B (zh) * 2023-07-10 2025-01-21 张琦 一种褐藻多糖衍生物纳米胶束的制备及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
US6689762B1 (en) * 1998-02-09 2004-02-10 Enzon Pharmaceuticals, Inc. Composition and methods for treatment of HIV infection
AU1182300A (en) * 1998-11-17 2000-06-05 Fuji Photo Film Co., Ltd. Bisaryl compounds and cancer remedies containing the same
AU6894400A (en) * 1999-08-06 2001-03-05 Enzon Pharmaceuticals Inc. Composition and methods for treatment of HIV infection
CA2407799A1 (fr) 2000-05-02 2001-11-08 Sugen, Inc. Derives d'acide acetique (2-oxindole-3-ylidenyl) et leur utilisation comme inhibiteurs de la proteine kinase
EP1313742A1 (fr) 2000-08-31 2003-05-28 Dr. Reddy's Laboratories Ltd. Procede de preparation d'hydrates d'olanzapine et de conversion de ceux-ci en formes cristallines d'olanzapine
PT1537878E (pt) 2002-07-03 2010-11-18 Ono Pharmaceutical Co Composições de imunopotenciação
US20060128783A1 (en) * 2002-08-09 2006-06-15 Dinsmore Christopher J Tyrosine kinase inhibitors
RU2383536C2 (ru) * 2004-08-04 2010-03-10 Тайсо Фармасьютикал Ко., Лтд. Производное триазола
MY142304A (en) 2005-01-31 2010-11-15 Taiho Pharmaceutical Co Ltd Novel pyrimidine nucleoside compound or salt thereof
TW200736234A (en) * 2006-01-17 2007-10-01 Astrazeneca Ab Chemical compounds
ES2458615T3 (es) * 2006-02-03 2014-05-06 Taisho Pharmaceutical Co., Ltd. Derivado de triazol
KR20100031528A (ko) * 2007-06-01 2010-03-22 더 트러스티즈 오브 프린스턴 유니버시티 숙주세포 대사경로의 조절을 통한 바이러스 감염 치료
WO2009023509A2 (fr) * 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Combinaisons thérapeutiques utiles pour traiter les maladies liées au cftr
JP2012508215A (ja) 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
WO2011071565A1 (fr) 2009-12-11 2011-06-16 Exelixis, Inc. Agonistes de tgr5
EP2552453A2 (fr) 2010-03-30 2013-02-06 Clavis Pharma ASA Procédés d'amélioration du cancer
TWI623316B (zh) 2015-12-22 2018-05-11 Taiho Pharmaceutical Co Ltd Antitumor effect enhancer derived from pyrrolopyrimidine compound
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP3424505A4 (fr) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. Préparation et composition de traitement de tumeurs malignes
AU2017275209C1 (en) 2016-05-31 2020-01-23 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
US10889555B2 (en) 2016-05-31 2021-01-12 Taiho Pharmaceutical Co., Ltd. Sulfonamide compound or salt thereof
US20200405697A1 (en) 2017-11-29 2020-12-31 Taiho Pharmaceutical Co., Ltd. Antitumor Agent
AU2018377036B2 (en) 2017-11-29 2022-04-14 Taiho Pharmaceutical Co., Ltd. Sulfonamide compounds and use thereof

Also Published As

Publication number Publication date
AU2017275209B2 (en) 2019-10-03
KR102311737B1 (ko) 2021-10-12
TWI746562B (zh) 2021-11-21
EP3466934A1 (fr) 2019-04-10
US11634395B2 (en) 2023-04-25
MX385269B (es) 2025-03-14
PH12018502513A1 (en) 2019-10-21
RU2732572C2 (ru) 2020-09-21
HUE067028T2 (hu) 2024-09-28
US20200399235A1 (en) 2020-12-24
DK3466934T3 (da) 2024-04-15
WO2017209155A1 (fr) 2017-12-07
KR20190015731A (ko) 2019-02-14
CN109563057A (zh) 2019-04-02
JP6532607B2 (ja) 2019-06-19
PT3466934T (pt) 2024-04-30
EP3466934A4 (fr) 2019-12-11
CN109563057B (zh) 2022-06-24
CA3025887A1 (fr) 2017-12-07
RU2018145761A3 (fr) 2020-07-10
SG11201810704WA (en) 2018-12-28
JPWO2017209155A1 (ja) 2019-04-18
RU2018145761A (ru) 2020-07-10
ES2982299T3 (es) 2024-10-15
KR20210093395A (ko) 2021-07-27
AU2017275209A1 (en) 2019-01-17
KR102543559B1 (ko) 2023-06-13
FI3466934T3 (fi) 2024-04-23
MX2018014762A (es) 2019-04-25
TW201800395A (zh) 2018-01-01
AU2017275209C1 (en) 2020-01-23
CA3025887C (fr) 2022-06-28
BR112018074646A2 (pt) 2019-03-06
MY194676A (en) 2022-12-13
EP3466934B1 (fr) 2024-03-27
PL3466934T3 (pl) 2024-06-10

Similar Documents

Publication Publication Date Title
IL286839A (en) Propyne-indole compounds
EP3466934A4 (fr) Composé de sulfonamide ou son sel
EP3381896A4 (fr) Nouveau composé de biphényle ou un sel de celui-ci
DK3692040T3 (da) Kemiske forbindelser
EP3534711A4 (fr) Combinaisons fongicides
BR112017018755A2 (pt) compostos bicíclicos de cetona sulfonamida.
EP3480198A4 (fr) Nouveau composé ou son sel pharmaceutiquement accepté
MA50466A (fr) Nouveau composé de biphényle ou sel de celui-ci
EP3609871A4 (fr) Composés d'amide aryl cyclopropyl-amino-isoquinolinyl
PT4039675T (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
EP3354638A4 (fr) Composé de phtalonitrile
EP3299355A4 (fr) Composé de phtalonitrile
LT3464336T (lt) Junginiai
EP3467106A4 (fr) Composé peptidique
BR112017017193A2 (pt) compostos herbicidas
EP3438103A4 (fr) Composé de griséofulvine
EP3533799A4 (fr) Composé
MA47129A (fr) Sel de composé pipéridine substitué
IL259918B (en) Alkyl dihydroquinoline sulfonamide compounds
EP3381916A4 (fr) Composé pyrimidine condensé ou sel de celui-ci
MA50937A (fr) Nouveau composé isoxazole ou sel de celui-ci
MA43275A (fr) Composé de pyranodipyridine
DK3672941T3 (da) Pyridylpyridonforbindelser
EP3686191A4 (fr) Composé de sulfamide cristallin
DK3672962T3 (da) Morpholinylpyridonforbindelser